Trial Profile
A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jul 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Ganitumab (Primary)
- Indications Germ cell and embryonal neoplasms; Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2022 Results of the completed phase I study presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 17 Mar 2022 Number of treatment arms have been decreased from 2 to 3 by the addition of Experimental: Phase 1 Dose Level 2: Ganitumab and Dasatinib arm.
- 17 Mar 2022 Status changed from completed to discontinued because the pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.